Sabby Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Sabby Management’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-16,705	Closed	-$48K	–	215
2017 Q4	$48K	Buy	+16,705	New	+$60.7K	﹤0.01%	143
2016 Q2	–	Sell	-105,648	Closed	-$906K	–	362
2016 Q1	$816K	Buy	+105,648	New	+$774K	0.04%	172
2015 Q3	–	Sell	-18,835	Closed	-$153K	–	421
2015 Q2	$167K	Sell	18,835 -94,869	-83%	-$897K	0.01%	302
2015 Q1	$1.12M	Sell	113,704 -890,483	-89%	-$11.1M	0.05%	182
2014 Q4	$12.3K	Buy	1,004,187 +946,216	+1,632%	+$11.6M	0.39%	35
2014 Q3	$579	Buy	+57,971	New	+$538K	0.02%	175
2014 Q1	–	Sell	-453,380	Closed	-$1.59M	–	288
2013 Q4	$1.5M	Sell	453,380 -31,499	-6%	-$91.4K	0.1%	96
2013 Q3	$1.46M	Buy	+484,879	New	+$3.32M	0.1%	103

Other funds holding ACHN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Sabby Management's ACHN Position: Q1 2018 in Review

Sabby Management sold out of Achillion Pharmaceuticals (ACHN) in Q1 2018, closing a stake of 16,705 shares — an estimated $48K sold.

Sabby Management first reported a position in ACHN in Q3 2013 and held it in 8 quarters. The position peaked at $1.5M in Q4 2013. 127 funds tracked by Wall St. Rank hold ACHN as of Q1 2018.

Sabby Management reported no remaining Achillion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Sabby Management sold 16,705 Achillion Pharmaceuticals shares in Q1 2018, an estimated $48K.
Sabby Management first reported a position in Achillion Pharmaceuticals in Q3 2013 and held it in 8 quarters.
Sabby Management's Achillion Pharmaceuticals position peaked at $1.5M in Q4 2013.
127 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2018.

Based on Sabby Management's 13F filing for Q1 2018, filed 15 May 2018.